Continuing Medical Education: Primary Care CME 2010: Neurology CME 2010: Measuring Lipids in Patients with Bipolar Disorder: Why We Must: CME Outfitters: Live Webcast: December 1, 2010 - December 1, 2011
http://www.cmenetworks.com/cme/11668/1/Continuing-Medical-Education-Primary-Care-CME-2010--Neurology-CME-2010--Measuring-Lipids-in-Patients-with-Bipolar-Disorder-Why-We-Must-CME-Outfitters-Live-Webcast-December-1-2010---December-1-2011/Page1.html
CME Outfitters
CME Outfitters is an independent accredited healthcare communications agency providing multidisciplinary continuing medical education content development, production, marketing, accreditation, and project management services to the healthcare industry.
By CME Outfitters
Published on 11/2/2010
Measuring Lipids in Patients with Bipolar Disorder: Why We Must
CME Outfitters, LLC
December 1, 2010 - December 1, 2011
The goal of this activity is to increase clinician knowledge of and performance against the STABLE measure related to assessment of hyperlipidemia in patients with bipolar disorder who are being treated with an atypical antipsychotic agent.
CME Sponsor:
CME Outfitters, LLC
Location: Live Webinar
Course Directors/Instructors:
David C. Henderson, MD
Associate Professor of Psychiatry
Harvard Medical School
Director, Schizophrenia, Diabetes, and
Weight Reduction Research Program
Director, The Chester M. Pierce, MD Division of
Global Psychiatry
Massachusetts General Hospital
Boston, MA
Roger S. McIntyre, MD, FRCPC
Associate Professor of Psychiatry and Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Toronto, ON
Moderator
Paul E. Keck, Jr., MD
President-CEO, Lindner Center of HOPE
Professor of Psychiatry & Behavior Neuroscience
University of Cincinnati College of Medicine
Cincinnati, OH
Number of Credits:
1.0 AMA PRA Category 1 Credit™
Registration Fee: Free
More Info
Detailed Description:
The Standards for Bipolar Excellence (STABLE) project outlined 15 evidence-based measures for quality assessment and improvement of care for patients with bipolar disorder (BPD). One of these relates to lipid measurement and assesses “the percentage of patients diagnosed with bipolar disorder and treated with an atypical antipsychotic agent who receive at least one assessment for hyperlipidemia within the initial 16 weeks of treatment.” This STABLE measure is based on joint recommendations from the American Psychiatric Association (APA) and the America Diabetes Association (ADA) and the fact that studies quantifying levels of clinician performance reveal that this assessment is underperformed. This educational intervention is designed to help you improve your practice by addressing clinician gaps in and health system barriers to implementation of consistent lipid measurement. Thus, neuroscienceCME Live and On Demand activity will provide the rationale for lipid measurement in bipolar disorder pharmacotherapy and strategies for increasing the frequency with which you perform it and respond appropriately to test results.
Learning Objectives:
At the end of this CE activity, participants should be able to:
Physicians, physician assistants, nurses, nurse practitioners, psychologists, pharmacists, social workers, certified case managers, and other healthcare professionals with an interest in bipolar disorder.
Measuring Lipids in Patients with Bipolar Disorder: Why We Must
CME Outfitters, LLC
December 1, 2010 - December 1, 2011
The goal of this activity is to increase clinician knowledge of and performance against the STABLE measure related to assessment of hyperlipidemia in patients with bipolar disorder who are being treated with an atypical antipsychotic agent.
Measuring Lipids in Patients with Bipolar Disorder: Why We Must
CME Sponsor:
CME Outfitters, LLC
Location: Live Webinar
Course Directors/Instructors:
David C. Henderson, MD
Associate Professor of Psychiatry
Harvard Medical School
Director, Schizophrenia, Diabetes, and
Weight Reduction Research Program
Director, The Chester M. Pierce, MD Division of
Global Psychiatry
Massachusetts General Hospital
Boston, MA
Roger S. McIntyre, MD, FRCPC
Associate Professor of Psychiatry and Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Toronto, ON
Moderator
Paul E. Keck, Jr., MD
President-CEO, Lindner Center of HOPE
Professor of Psychiatry & Behavior Neuroscience
University of Cincinnati College of Medicine
Cincinnati, OH
Number of Credits:
1.0 AMA PRA Category 1 Credit™
Registration Fee: Free
More Info
Detailed Description:
The Standards for Bipolar Excellence (STABLE) project outlined 15 evidence-based measures for quality assessment and improvement of care for patients with bipolar disorder (BPD). One of these relates to lipid measurement and assesses “the percentage of patients diagnosed with bipolar disorder and treated with an atypical antipsychotic agent who receive at least one assessment for hyperlipidemia within the initial 16 weeks of treatment.” This STABLE measure is based on joint recommendations from the American Psychiatric Association (APA) and the America Diabetes Association (ADA) and the fact that studies quantifying levels of clinician performance reveal that this assessment is underperformed. This educational intervention is designed to help you improve your practice by addressing clinician gaps in and health system barriers to implementation of consistent lipid measurement. Thus, neuroscienceCME Live and On Demand activity will provide the rationale for lipid measurement in bipolar disorder pharmacotherapy and strategies for increasing the frequency with which you perform it and respond appropriately to test results.
Learning Objectives:
At the end of this CE activity, participants should be able to:
- Identify strategies to overcome barriers that hinder lipid measurement.
- Increase the rate at which you perform at least one assessment for hyperlipidemia within the initial 16-week
- treatment period among patients with BPD who are being treated with an atypical antipsychotic agent, in
- accordance with the STABLE measure regarding lipid assessment.
- Select an appropriate clinical strategy for addressing an abnormal lipid test.
- Explain the rationale for measuring lipids in patients with BPD who take atypical antipsychotic agents in order to
- Describe a patient-centered strategy that will help patients with BPD obtain blood draws for needed laboratory tests.
Physicians, physician assistants, nurses, nurse practitioners, psychologists, pharmacists, social workers, certified case managers, and other healthcare professionals with an interest in bipolar disorder.